Seeking Alpha
View as an RSS Feed

Spencer Osborne  

View Spencer Osborne's Comments BY TICKER:
Latest  |  Highest rated
  • Vivus: Weight Loss Sector Or Erectile Dysfunction - Pick Your Poison [View article]
    Long....

    Read the entire form 4. On the form there is a section for explanations. By example, this is on the Wesley Day form.


    Explanation of Responses:
    ( 1) Sold to pay the tax libility resulting from the vesting of 18,000 restricted stock units granted on January 22, 2014.

    It is very common for sales to be made to cover the taxes or expenses related to options being granted or vested.
    Jul 28, 2015. 12:59 PM | 1 Like Like |Link to Comment
  • Vivus: Weight Loss Sector Or Erectile Dysfunction - Pick Your Poison [View article]
    SI.....

    You certainly do not need to read all of my articles. However, you should not jump to a conclusion either. I have combined sector wide articles in the past. That typically brings out a bunch of trolls touting the particular equity they are invested in touting anything and everything except what should really be discussed. For some reason there is a contingent of trolls (ARNA seems to have the most these days) that feel all others need to fail rather than realizing that the sector needs overall success to drive real changes.

    Weekly script numbers are pretty straight forward. The sales numbers across the board are not where they need to be.
    Jul 28, 2015. 09:14 AM | Likes Like |Link to Comment
  • Vivus: Weight Loss Sector Or Erectile Dysfunction - Pick Your Poison [View article]
    sI....

    You seem to put a lot of imagination into what you think I am saying. Why not ask a question instead of making a bad assumption. If you read what I have written in the past you would no I do not give a damn about my investment status in an equity with regard to what I write about a company, and certainly do not get into the business of hit pieces. If I wanted t pen a hit piece about any of these companies it would be about 10 times more critical than it is. Hit pieces and pump pieces are not part of how I do business. I have hundreds of articles that demonstrate that.

    I am saying that the weight loss sector is sucking wind.

    I am saying that Vivus can not sell enough Qsymia to turn the tide.

    I am saying that Vivus may see a pop on stendra numbers

    Now, you can play the role of a naive,entail moron and assume the things you have, or you could discuss important things.

    Half of your post decent and relevant to meaningful discussion. The other half is the stuff of mental morons that live on message boards. Please, you exhibit some level of intelligence. Stop the BS stuff.
    Jul 27, 2015. 07:55 PM | 1 Like Like |Link to Comment
  • Orexigen: Contrave Sales Up 2.75% - Still No News On Europe [View article]
    Wendel....

    Yes. A travesty. Any person that looks at the go aces of it will see that one and only conclusion. It has decimated the middle class, small and medium businesses, and made good insurance unaffordable. The American people dislike it, and that dislike increases each year as premiums continue to skyrocket along with deductibles. The only thing going down us the quality if care and access to care.
    Jul 27, 2015. 05:57 PM | 1 Like Like |Link to Comment
  • Orexigen: Contrave Sales Up 2.75% - Still No News On Europe [View article]
    John.....

    There are examples of good results with all of these drugs. The problem is that none of them is a ultimate solution. Consumers do not understand what they should. Refills only last about 3 months, then a new crop of consumers is needed. These drugs need to be able to keep patients on longer.
    Jul 27, 2015. 04:13 PM | 1 Like Like |Link to Comment
  • Orexigen: Contrave Sales Up 2.75% - Still No News On Europe [View article]
    Uber....

    I am not holding my breath....unless somehow there has been some big action under the radar.
    Jul 27, 2015. 04:11 PM | 1 Like Like |Link to Comment
  • Vivus: Weight Loss Sector Or Erectile Dysfunction - Pick Your Poison [View article]
    Max.....

    I cover the sector. My investments in this sector are very modest. I do not let my stakes dictate what I write. If you read my articles you will see that demonstrated very clearly. Now, you could deflect from the real discussion and talk about me, or you could discuss the things that really matter. Your choice us telling.

    Are you happy with scripts in the sector?

    Are you happy with Qsymia scripts?

    What type of revenue do you think stendra will bring?

    Do you think that stendra sakes Dan carry this company?

    These are meaningful discussion points. Thinking I attack one company over another is deflection.
    Jul 27, 2015. 04:09 PM | 1 Like Like |Link to Comment
  • Vivus: Weight Loss Sector Or Erectile Dysfunction - Pick Your Poison [View article]
    User....

    I follow many things. Have covered stendra in many articles
    Jul 27, 2015. 12:52 PM | Likes Like |Link to Comment
  • Vivus: Weight Loss Sector Or Erectile Dysfunction - Pick Your Poison [View article]
    User....

    There are investors that hold out hope. It is amazing to see, but it does exist
    Jul 27, 2015. 12:51 PM | 2 Likes Like |Link to Comment
  • Arena: Sales Flat Again - Belviq Still Losing Market Share [View article]
    User....

    It works for some people.

    I would say 25% respond well, 25% respond okay, 50% do not respond.
    Jul 27, 2015. 12:05 PM | 2 Likes Like |Link to Comment
  • Orexigen: Contrave Sales Up 2.75% - Still No News On Europe [View article]
    Y....

    U.S. Senate will not move. The travesty that is obamacare has ensured that.
    Jul 27, 2015. 11:58 AM | 1 Like Like |Link to Comment
  • EnteroMedics - De-Listing Process Should Be Front And Center With Investors [View article]
    Jose.....

    Yea right
    Jul 25, 2015. 11:24 AM | Likes Like |Link to Comment
  • EnteroMedics - De-Listing Process Should Be Front And Center With Investors [View article]
    Jose....

    Say it a fifth time. Does not change the fact I have been spot on
    Jul 23, 2015. 03:00 PM | 1 Like Like |Link to Comment
  • EnteroMedics - De-Listing Process Should Be Front And Center With Investors [View article]
    Jose....

    Kindly read what I wrote three months ago and come to the realization that I was spot on.

    Cheers
    Jul 23, 2015. 03:00 PM | Likes Like |Link to Comment
  • Orexigen: Contrave Sales Continue To Grab Market Share - Still Not Enough [View article]
    George....

    1. I favor novo nordisk as an investment despite the fact that the company is in the anti obesity space. Novo is, in my opinion, head and shoulders above arena in terms of an investment. That opinion is because of everything else novo has and has nothing to do with Saxenda.

    2. Saxenda is at a bit over 1,000 scripts a week at this stage. Actually, considering the cost, the progress is pretty impressive.
    Jul 23, 2015. 02:07 PM | 1 Like Like |Link to Comment
COMMENTS STATS
8,855 Comments
7,451 Likes